Drug Profile

GLPG 4605

Alternative Names: GLPG-4605

Latest Information Update: 22 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Galapagos NV
Class Antifibrotics; Small molecules
Mechanism of Action Salt-inducible kinase 3 inhibitors; Salt-inducible kinase-2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

31 Dec 2022 Discontinued - Preclinical for Fibrosis in Belgium (unspecified route)
22 Jan 2021 GLPG 4605 is available for licensing as of 22 Jan 2021. https://www.glpg.com/partnering
27 Oct 2020 Preclinical trials in Fibrosis in Belgium (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com